First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ...
Mr. Kenyon has served as the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as ...
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...
Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...
GlobalData on MSN7d
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trialThe Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...
On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...
BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...
Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.
Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical ...
In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback